Profiel
Theresa Mansi is associated with NexEos Diagnostics, Inc. and NexEos Bio, Inc. as the Chief Executive Officer and Director, and Chief Executive Officer respectively.
Actieve functies van Theresa Mansi
Bedrijven | Functie | Begin |
---|---|---|
NexEos Diagnostics, Inc.
NexEos Diagnostics, Inc. Medical/Nursing ServicesHealth Services NexEos Diagnostics, Inc. operates as a medical diagnostics company focuses on disorders related to white blood cells. The company is headquartered in Wayne, PA. | Algemeen Directeur | - |
NexEos Bio, Inc.
NexEos Bio, Inc. Medical/Nursing ServicesHealth Services NexEos Bio is a medical diagnostics company that aims to improve the detection, diagnosis, treatment, and management of patients with chronic, eosinophil-related inflammatory diseases. The company is based in Wayne, PA. The company's lead program is a non-invasive imaging agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis (EoE). This program has the potential to improve patients' quality of life, more rapidly diagnose their disease, and may help delay disease progression. The company was founded by Gerald Gleich, and the CEO is Theresa Mansi. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
NexEos Diagnostics, Inc.
NexEos Diagnostics, Inc. Medical/Nursing ServicesHealth Services NexEos Diagnostics, Inc. operates as a medical diagnostics company focuses on disorders related to white blood cells. The company is headquartered in Wayne, PA. | Health Services |
NexEos Bio, Inc.
NexEos Bio, Inc. Medical/Nursing ServicesHealth Services NexEos Bio is a medical diagnostics company that aims to improve the detection, diagnosis, treatment, and management of patients with chronic, eosinophil-related inflammatory diseases. The company is based in Wayne, PA. The company's lead program is a non-invasive imaging agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis (EoE). This program has the potential to improve patients' quality of life, more rapidly diagnose their disease, and may help delay disease progression. The company was founded by Gerald Gleich, and the CEO is Theresa Mansi. | Health Services |